NAD+ Precursors vs. Antioxidants for Dog Aging: My Verdict on Which One Earns a Spot in the Bowl

By Cheryl Chrisman, DVM, MSTCVM, CVA, CVCH, CVTP, CVFT

Comparisons · August 16, 2026 · 7 min read

NAD+ precursors target cellular energy machinery; antioxidants mop up damage already done — the science favors combining both, not choosing one.

The Checklist Before You Pick a Lane

Before you read another word of marketing copy, run your dog’s case against this:

• Is the concern cognitive (disorientation, sleep-wake reversal, house-soiling, staring at walls) or physical (stiffness, exercise intolerance, slower recovery)? NAD+ precursor research to date leans cognitive; antioxidant research has the longer track record on brain aging specifically.
• How old, and how fast is the change? A gradual six-month drift argues for a diet-level antioxidant strategy. A sharper decline over weeks argues for a veterinary workup first — supplements are not a diagnostic substitute.
• What’s the pill burden your dog and your schedule can actually sustain? Some NAD+ precursor protocols are daily-plus-monthly dosing; that adherence math matters more than the ingredient panel.
• Has the product actually been dosed in dogs, or is the NAD+/antioxidant claim extrapolated from human or rodent data? Say this out loud, because a lot of the category has not cleared that bar.
• Does the brand carry the NASC Quality Seal or equivalent third-party manufacturing oversight? It doesn’t prove efficacy, but it rules out a category of preventable harm.

My call, up front: for a dog with owner-observed cognitive slippage, I lean toward a formula pairing a senolytic with an NAD+ precursor, because it is the only approach in this comparison with a peer-reviewed, placebo-controlled trial behind it. For general aging support without a cognitive complaint, a diet or supplement built around a comprehensive antioxidant blend has the deeper, older evidence base. I rarely pick one and discard the other — I sequence them, and I’ll show you how below.

The Limitation Nobody Puts on the Label

Here is what the marketing rarely says out loud: neither category has been shown to add years to a dog’s life. Not one. What both categories have, to varying degrees, is evidence of supporting function — slowing a measurable decline, not reversing aging itself. That distinction should govern how you read every claim that follows, including mine.

In my practice, I set the nervous-system mechanism beside the whole-patient pattern before I say a word about supplements. A cellular energy deficit and a system-wide inflammatory or oxidative burden are not competing explanations for canine aging — they are usually both present, in different proportions, in the same dog. Treating the comparison as an either/or question is where most of the confusion in this category starts.

Myth: They’re Interchangeable “Longevity” Tools

The myth I hear most often in the exam room is that NAD+ precursors and antioxidants are two brands of the same idea — pick whichever one is cheaper or better reviewed. They are not. NAD+ precursors (nicotinamide riboside and related compounds) are substrates: they feed a cofactor, NAD+, that cells use for energy production and DNA repair signaling, and levels of that cofactor decline with age. Antioxidants are scavengers: they neutralize reactive oxygen species that accumulate as a byproduct of normal metabolism and inflammation. One is upstream fuel; the other is downstream cleanup. A dog can plausibly need more of one, the other, or both, depending on where the burden actually sits.

What NAD+ Precursors Are Actually Built to Do

The strongest data point in this entire category comes from a randomized, placebo-controlled trial in senior dogs with mild to moderate cognitive impairment, published in Scientific Reports. Seventy dogs were split into placebo, low-dose, and full-dose groups receiving a combination NAD+ precursor and senolytic compound (the compound, LY-D6/2, underpins the Leap Years line — one of the few products in this space built directly from a named clinical trial rather than borrowed human data). Owner-reported cognitive dysfunction scores improved significantly more in the full-dose group than placebo over the study period, alongside changes in measured activity levels.

That is a real signal, and it is more than most ingredients in the pet supplement aisle can claim. It is also one trial, with owner-reported outcomes as a primary endpoint, in dogs already showing cognitive impairment — not a healthy-aging or lifespan claim, and not yet replicated by an independent lab. I’d rather be honest about that ceiling than let a single strong study get inflated into a category-wide guarantee.

What Antioxidants Are Actually Built to Do

Antioxidants have the longer institutional track record, and the mechanism is more thoroughly worked out. A now-classic diet study found that senior beagles fed a diet enriched with antioxidant-rich fruits and vegetables made fewer errors on complex learning tasks than dogs on a standard diet, with the antioxidant group also showing lower markers of oxidative damage, according to research published via PubMed. A more recent review of antioxidant strategies for age-related oxidative damage in dogs, indexed on PMC, notes that single-ingredient antioxidants such as vitamin E or vitamin C alone tend to underperform comprehensive blends that combine several antioxidant sources with fatty acids and B vitamins — the synergy, not any one molecule, appears to be doing the work.

The honest caveat here: antioxidants reduced oxidative damage and improved specific cognitive test performance, but they did not prevent the underlying neuronal loss that drives canine cognitive dysfunction. That’s structure-and-function support, not disease reversal, and I say that as the floor of the claim, not an apology for it.

A Pattern I’ve Watched Repeat in Exam Rooms

One of the dogs on my neurology caseload was a twelve-year-old spayed female Cavalier King Charles Spaniel, about 16 pounds, whose owner first noticed her pacing at the foot of the stairs around 9 p.m. instead of settling in her usual spot by the fireplace. That started in late autumn, and by the following February the owner was also seeing her stand at the wrong side of a closed door and occasionally miss the last step going up. The owner’s tradeoff wasn’t cost — it was pill burden on top of an existing seizure medication schedule, and whether the dog would even tolerate one more capsule twice a day. We started with a single, well-sourced antioxidant-forward formula rather than layering in a second NAD+ precursor product, specifically because the medication load was already high and I wanted one clean variable to evaluate. Over about ten weeks, the pacing pattern softened and the stair-miss stopped recurring, which I noted in the chart as a single case, not proof of anything beyond that one dog’s response.

Where the Evidence Is Strong, Thin, or Mixed

Scored plainly: NAD+ precursor-plus-senolytic combinations are strong for owner-reported cognitive dysfunction in one peer-reviewed trial, thin for lifespan or broad healthy-aging claims, and untested for dogs without cognitive symptoms. Antioxidant blends are strong for reducing measurable oxidative stress markers and supporting learning-task performance in controlled diet studies, moderate for translating that into visible at-home behavior change, and thin as single-ingredient interventions rather than comprehensive blends. Neither category has controlled trial evidence for extending a dog’s lifespan, and I would treat any product implying otherwise as a red flag regardless of which ingredient it’s built around.

The Sequence I Actually Recommend

Start with the presenting problem, not the ingredient. If the concern is cognitive — disorientation, altered sleep, house-soiling in a previously reliable dog — I bring up the NAD+ precursor-plus-senolytic evidence first, because it’s the only branch of this comparison with a placebo-controlled trial behind a cognitive endpoint. If the concern is general aging support without a cognitive complaint, I start with a comprehensive antioxidant approach, ideally diet-level before supplement-level, because that’s where the deepest evidence sits. Either way, confirm third-party manufacturing oversight — the NASC Quality Seal is the most widely recognized marker in this category — and buy from a source you can verify is brand-authorized; see our breakdown of Amazon Marketplace vs. brand-direct websites if that’s where you’re shopping. Form matters too: a dog that spits out capsules won’t get a fair trial of either ingredient, which is why I point owners toward our comparison of chew, powder, and liquid supplement formats before committing to a product. And if stiffness is part of the picture alongside cognitive change, don’t let the two get conflated — our guide to arthritis vs. normal aging stiffness walks through how to tell them apart before you add anything to the bowl.

I’ve watched owners try to solve a cognitive problem with a joint-focused antioxidant blend, and stiffness with an NAD+ precursor sold for brain aging, simply because both products used the word “longevity” on the label. Match the mechanism to the symptom first. The ingredient panel is the second decision, not the first.

Where This Leaves the Verdict

My bottom line: these are not rival products competing for the same job, and treating them that way is the single most common mistake I see in this category. NAD+ precursors, backed now by one solid trial, earn their place when the presenting problem is cognitive. Antioxidants, backed by a longer and broader evidence base, earn their place as the more general aging-support strategy, and they combine reasonably with an NAD+ precursor rather than compete against it. What neither earns, on the evidence available today, is a claim on your dog’s lifespan — and I’d be skeptical of any brand that tells you otherwise.